OHSS After IVF: Symptoms, Classification, Prevention & Treatment

Medical disclaimer: This article is written for educational purposes and does not constitute medical advice. OHSS can become a medical emergency. If you are undergoing ovarian stimulation and develop significant abdominal pain, rapid weight gain, or difficulty breathing, contact your clinic immediately or go to the nearest emergency department. Always follow the specific guidance of your treating physician.

Ovarian hyperstimulation syndrome (OHSS) is the most significant iatrogenic complication of IVF and other assisted reproductive technology (ART) protocols. It occurs when the ovaries respond excessively to fertility medications, leading to fluid shifts out of the vascular space and into body cavities. Mild forms are common and self-limiting; severe and critical forms can be life-threatening and require hospitalisation.

Understanding OHSS — its mechanism, risk factors, early warning signs, and how modern protocols have dramatically reduced its incidence — is essential for anyone undergoing ovarian stimulation. This guide synthesises current clinical evidence and guidelines from the American Society for Reproductive Medicine (ASRM) and the European Society of Human Reproduction and Embryology (ESHRE).

What Causes OHSS? The Pathophysiology

The central driver of OHSS is vascular endothelial growth factor (VEGF), a signalling protein produced by granulosa cells in ovarian follicles. Under normal stimulation, VEGF is produced in modest amounts. In an exaggerated ovarian response — particularly when hCG (human chorionic gonadotropin) is administered to trigger ovulation — a large cohort of follicles produces a surge of VEGF that dramatically increases vascular permeability.

This increased permeability causes fluid (predominantly protein-rich plasma) to leak out of blood vessels into third spaces: most commonly the peritoneal cavity (causing ascites), but also the pleural space (causing pleural effusion) and, in severe cases, the pericardium. The result is a simultaneous contraction of intravascular volume — leading to haemoconcentration, reduced kidney perfusion, and risk of thrombosis — alongside distension of body cavities with fluid.

The process is amplified when a pregnancy establishes, because the developing embryo produces its own hCG, which continues to stimulate the hypersensitised ovaries. This is why "late-onset OHSS" (occurring more than 10 days after trigger) is almost always associated with a positive pregnancy test, and why freeze-all strategies (freezing all embryos rather than proceeding to fresh transfer) are one of the most effective preventive measures available.

Who Is at Risk? Risk Factors for OHSS

Not every patient undergoing IVF faces the same OHSS risk. Recognising high-risk individuals before stimulation begins allows the clinical team to tailor the protocol accordingly.

High-risk patient characteristics:

• Polycystic ovary syndrome (PCOS) — the single strongest predictor; PCOS patients have a higher basal antral follicle count and are hyperresponsive to gonadotropins. For more on PCOS and fertility, see the PCOS fertility hub.
• Young age (under 35) — associated with higher ovarian reserve and greater gonadotropin sensitivity
• Low body weight / low BMI — reduced volume of distribution for gonadotropins, higher drug concentration per kilogram
• Elevated baseline AMH (above 3.5 ng/mL / 25 pmol/L) — a reliable predictor of excessive follicular response
• High antral follicle count (AFC) — an AFC above 15–20 is associated with significantly increased OHSS risk
• Previous history of OHSS — the strongest retrospective predictor
• Large number of oocytes retrieved — retrieval of more than 15 oocytes is associated with increased risk; more than 20 is considered high-risk
• Rapidly rising or very high estradiol levels during stimulation (above 3,000–4,000 pg/mL)

Conversely, patients with diminished ovarian reserve typically face very low OHSS risk due to poor ovarian response, though this comes with its own challenges for IVF outcomes.

OHSS Classification: Mild, Moderate, Severe, and Critical

OHSS exists on a spectrum. The classification system most widely used in clinical practice is that adopted by ESHRE and reflected in the ASRM Practice Committee guidelines. The table below summarises the key features of each severity grade.

Mild OHSS affects 20–33% of all IVF stimulation cycles and is generally considered an expected physiological response rather than a complication. Moderate OHSS affects approximately 3–6%, and severe OHSS occurs in 0.1–2% of cycles. Critical OHSS is rare but has been associated with maternal mortality, underscoring why prevention is the primary clinical priority.

Early-Onset vs. Late-Onset OHSS

A clinically important distinction is between early-onset OHSS (occurring within 9 days of the trigger injection, driven by exogenous hCG) and late-onset OHSS (occurring 10 or more days after trigger, driven by endogenous hCG from an implanting embryo). Late-onset OHSS tends to be more severe and protracted, because rising pregnancy hCG continues to stimulate sensitised ovarian tissue. This is the primary rationale for the freeze-all strategy in high-risk patients — by deferring embryo transfer to a subsequent cycle, the stimulus for late-onset OHSS is removed entirely.

Prevention Strategies: Evidence-Based Protocols

Modern IVF practice has made severe OHSS largely preventable. The following strategies, used individually or in combination, are supported by robust clinical evidence from ASRM and ESHRE guidelines.

1. GnRH Antagonist Protocols

The choice of stimulation protocol is the single most impactful prevention strategy. GnRH antagonist protocols (using medications such as cetrorelix or ganirelix to suppress premature LH surges) have largely superseded long GnRH agonist (down-regulation) protocols for high-risk patients because of one crucial advantage: they allow the use of a GnRH agonist trigger instead of hCG.

In antagonist protocols, a GnRH agonist such as leuprolide acetate (Lupron) or buserelin can be used to trigger the final oocyte maturation step. This produces a brief, physiological LH surge that is sufficient for oocyte maturation but resolves within 24–36 hours, in contrast to the prolonged (7–10 day) half-life of standard hCG triggers. The result is a dramatically reduced incidence of severe OHSS — several randomised controlled trials and the 2016 ESHRE guideline on ovarian stimulation confirm that GnRH agonist triggering in antagonist cycles reduces severe OHSS incidence to near zero in most high-risk patients.

2. Trigger Choice: GnRH Agonist Trigger and Dual Trigger

For patients on antagonist protocols who are identified as high-risk during stimulation, switching from an hCG trigger to a GnRH agonist trigger is the most effective single intervention to prevent severe OHSS. When some degree of luteal support is required (particularly if a fresh transfer is still planned), a dual trigger — combining a low dose of hCG with a GnRH agonist — may be used. A full agonist trigger without any hCG is preferred in the highest-risk cases where freeze-all is planned.

3. Freeze-All Strategy (Elective Cryopreservation)

In the highest-risk patients — those with extremely high AMH, AFC above 20, more than 15 follicles developing during stimulation, or pre-existing OHSS symptoms — freezing all embryos and deferring transfer to a subsequent frozen embryo transfer (FET) cycle eliminates the risk of late-onset OHSS entirely. The embryos are not lost; they are cryopreserved with high survival rates, and FET pregnancy rates are comparable to (and in some populations superior to) fresh transfer outcomes.

This strategy has become standard of care at most clinics for high-risk patients, particularly those with PCOS, and is endorsed by both ASRM and ESHRE. It also allows the endometrium, which may be suboptimal during a high-stimulation cycle, time to recover before transfer.

4. Gonadotropin Dose Reduction and "Coasting"

Careful individualisation of the starting gonadotropin dose based on AMH, AFC, age, and BMI reduces the likelihood of an excessive response. Dosing algorithms — rather than empirical "standard dose" approaches — are now the recommended approach. When hyperstimulation is already developing mid-cycle, coasting (withholding gonadotropins while continuing GnRH antagonist to prevent a premature LH surge) allows follicle numbers to stabilise and estradiol levels to fall before triggering.

5. Cabergoline and IV Albumin

Cabergoline, a dopamine agonist, inhibits VEGF receptor phosphorylation and has been shown in multiple randomised trials to reduce OHSS severity and the incidence of moderate OHSS, without affecting pregnancy rates. ESHRE guidelines support its use as a secondary prevention strategy at a dose of 0.5 mg daily for 8 days starting on the day of trigger.

Intravenous albumin (administered at oocyte retrieval) is used in selected high-risk patients to maintain oncotic pressure and reduce vascular permeability, particularly in severe cases or after retrieval of a very high number of oocytes (> 20).

Recognising OHSS: Symptoms and Home Monitoring

If you are in a high-risk category or have been told to watch closely after retrieval, knowing the warning signs allows you to act promptly.

Common early symptoms (usually develop 3–5 days after trigger or retrieval):

• Bloating and abdominal fullness
• Mild to moderate pelvic or lower abdominal pain
• Nausea, with or without vomiting
• Reduced urinary frequency

Symptoms suggesting moderate-to-severe OHSS:

• Rapid weight gain — more than 1 kg (2.2 lbs) per day or more than 3 kg in 3 days
• Significant abdominal distension with visible swelling
• Severe nausea and vomiting making it difficult to keep fluids down
• Shortness of breath, particularly when lying flat
• Decreased urination — going less than 3–4 times per day

Daily home monitoring is standard practice for at-risk patients. Your clinic will typically advise you to:

1. Weigh yourself every morning before eating, at the same time each day
2. Keep a fluid intake and urine output diary
3. Report a weight gain exceeding specified thresholds (usually 1 kg/day or 3 kg/week) immediately
4. Attend clinic for serial ultrasound and blood tests (haematocrit, electrolytes, renal function) as scheduled

When to Go to the Emergency Department

Contact your clinic immediately, or go directly to an emergency department if you cannot reach them, if you experience any of the following:

• Severe abdominal pain that is not relieved by paracetamol
• Difficulty breathing or shortness of breath at rest
• Fainting or dizziness on standing
• No urination for 12 or more hours
• Sudden onset of leg swelling, redness, or pain (possible deep vein thrombosis)
• Sudden sharp one-sided pelvic pain (possible ovarian torsion or rupture)
• Chest pain or palpitations

Severe OHSS poses a significant risk of thromboembolic events (blood clots in the legs or lungs) due to haemoconcentration and elevated clotting factors. This risk is further increased in pregnancy. Thromboprophylaxis with low-molecular-weight heparin is standard care for admitted patients.

Treatment of OHSS

Treatment is largely supportive and guided by severity:

• Mild: Oral hydration (isotonic fluids and electrolyte drinks; avoid plain water in excess), paracetamol for pain, rest, and daily symptom monitoring
• Moderate: Close outpatient follow-up with serial bloods; antiemetics; NSAIDs may be used cautiously early in the cycle (avoid once pregnancy confirmed)
• Severe: Hospital admission for IV fluids (normal saline or Ringer's lactate), IV albumin to restore oncotic pressure, daily renal function and electrolyte monitoring, thromboprophylaxis with low-molecular-weight heparin, and paracentesis (draining ascitic fluid via ultrasound-guided needle) when tense ascites is causing respiratory or renal compromise
• Critical: ICU management; possible pleural drainage; continuous monitoring for thromboembolic complications; multidisciplinary care

Prognosis: Does OHSS Affect Pregnancy Rates?

Mild and moderate OHSS are self-limiting conditions that resolve spontaneously over 10–14 days if pregnancy does not establish, or over 4–6 weeks if a pregnancy continues (as endogenous hCG continues to sustain ovarian stimulation). The condition does not damage fertility permanently.

Importantly, properly managed OHSS does not appear to adversely affect the pregnancy itself. Several large observational studies have found that hCG levels, implantation rates, and live birth rates are not significantly different in patients who developed moderate OHSS compared to those who did not. However, severe OHSS requiring hospitalisation and aggressive intervention carries maternal health risks that underscore the priority of prevention.

For a broader overview of IVF outcomes and success rates, including how various complications affect live birth rates by age group, consult the Fertlo data resource.

Choosing a Clinic with Strong OHSS Prevention Protocols

The protocols your clinic uses — particularly whether they individualise stimulation dosing, routinely use antagonist protocols for high-risk patients, and offer elective freeze-all — make a significant difference to your risk profile. When researching fertility clinics, ask prospective clinics:

• What proportion of your high-risk patients do you trigger with GnRH agonist?
• What is your severe OHSS hospitalisation rate?
• Do you routinely offer freeze-all for PCOS or high-responder patients?

These questions signal a clinic's commitment to evidence-based, patient-safe stimulation practice.

Frequently Asked Questions

Q: How common is OHSS with IVF?

Mild OHSS affects roughly 20–33% of all stimulated IVF cycles and is considered a predictable physiological response to ovarian stimulation. Moderate OHSS occurs in 3–6% of cycles. Severe OHSS — the form requiring hospitalisation — now occurs in fewer than 2% of cycles at centres using modern prevention protocols, and is substantially rarer with GnRH antagonist protocols and agonist triggering. Critical OHSS is rare but does occur, particularly when prevention strategies are not implemented in high-risk patients.

Q: Can I still get pregnant if I have OHSS?

Yes. Mild and moderate OHSS do not impair egg quality, embryo development, or implantation. If a fresh embryo transfer is cancelled due to high OHSS risk and all embryos are frozen, pregnancy outcomes from a subsequent frozen embryo transfer cycle are equivalent to — and in PCOS patients sometimes superior to — fresh transfer outcomes. Late-onset OHSS, paradoxically, is associated with successful implantation because the rising pregnancy hCG that drives it is a sign that a viable pregnancy has established.

Q: What should I eat and drink if I have mild OHSS?

Prioritise isotonic or protein-containing fluids — sports drinks (Gatorade, Lucozade Sport), coconut water, and high-protein soups are commonly recommended. Adequate protein intake helps maintain oncotic pressure and reduce fluid shifts. Avoid large volumes of plain water alone, as excessive plain water can dilute sodium and worsen symptoms. Small, frequent meals high in protein and low in refined carbohydrates are generally well tolerated. Your clinic will provide specific guidance based on your severity.

Q: How long does OHSS last?

If no pregnancy establishes, OHSS typically peaks around 7–10 days after the trigger injection and resolves when menstruation begins — usually within 14 days of onset. If a pregnancy establishes, OHSS can persist and even worsen for 4–6 weeks, gradually resolving as the placenta takes over hCG production and ovarian hyperstimulation diminishes. Severe cases may require weeks of medical management before full resolution.

Q: Is OHSS more likely with donor eggs or frozen embryo transfer?

No. OHSS is a complication of ovarian stimulation — it occurs in the patient whose ovaries are being stimulated to produce eggs. An egg donor may develop OHSS; the recipient (who is not being stimulated) does not. Similarly, patients undergoing frozen embryo transfer (FET) in a natural or medicated cycle without gonadotropin stimulation do not develop OHSS. This is the basis for the freeze-all strategy: by freezing embryos and doing an FET in a subsequent unstimulated cycle, OHSS risk is entirely eliminated for that transfer attempt.

Sources

1. American Society for Reproductive Medicine (ASRM) Practice Committee. Prevention and Treatment of Moderate and Severe Ovarian Hyperstimulation Syndrome. Fertil Steril. 2016;106(7):1634–1647. https://doi.org/10.1016/j.fertnstert.2016.08.048

2. ESHRE Guideline Group on Ovarian Stimulation. ESHRE guideline: ovarian stimulation for IVF/ICSI. Hum Reprod Open. 2020;2020(2):hoaa009. https://doi.org/10.1093/hropen/hoaa009

3. Humaidan P, Quartarolo J, Papanikolaou EG. Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil Steril. 2010;94(2):389–400.

4. Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update. 2002;8(6):559–577.

5. Mourad S, Brown J, Farquhar C. Interventions for the prevention of OHSS in ART cycles: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2017;1:CD012103.

6. Tang H, et al. Cabergoline for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev. 2012;2:CD008605.

7. Devroey P, Polyzos NP, Blockeel C. An OHSS-free clinic by segmentation of IVF treatment. Hum Reprod. 2011;26(10):2593–2597.